Trifluxen 15 mg + 6.14 mg (Trifluridine + Tipiracil)

Overview

Trifluxen 15 mg + 6.14 mg is an oral anticancer medicine manufactured by Everest Pharmaceuticals Ltd. It contains a fixed-dose combination of Trifluridine 15 mg and Tipiracil 6.14 mg, the same active ingredients found in the internationally recognized brand Lonsurf®. This targeted oral chemotherapy is specifically developed for patients with advanced gastrointestinal cancers who have already received multiple previous treatments.

The combination of trifluridine and tipiracil works synergistically to inhibit cancer cell growth while improving the stability and effectiveness of the active drug within the body. Trifluxen offers an important treatment option for patients with advanced or metastatic cancers when conventional chemotherapy and targeted therapies are no longer effective.

Administered under the supervision of an experienced oncologist, Trifluxen helps delay disease progression, extend overall survival, and maintain quality of life in patients with difficult-to-treat cancers.

Medical Uses of Trifluxen 15 mg + 6.14 mg

Trifluxen is approved for adult patients with advanced gastrointestinal malignancies after failure of standard therapies.

Metastatic Colorectal Cancer (mCRC)

Trifluxen is indicated for patients with metastatic colorectal cancer who have previously received standard treatment regimens, including:

• Fluoropyrimidine-based chemotherapy
• Oxaliplatin
• Irinotecan
• Anti-VEGF therapy
• Anti-EGFR therapy (when appropriate)

It is prescribed when the disease continues to progress despite these treatments.

 

Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Trifluxen is also used for patients diagnosed with:

• Advanced gastric cancer
• Gastroesophageal junction adenocarcinoma

The medicine is recommended after at least two prior systemic chemotherapy regimens have failed to control the disease.

Not a First-Line Therapy

Trifluxen is not intended as an initial treatment for colorectal or gastric cancer. Instead, it serves as an effective later-line therapy for patients with refractory or treatment-resistant disease, offering an additional opportunity to control tumor growth after standard options have been exhausted.

How Trifluxen Works

The effectiveness of Trifluxen comes from the complementary actions of its two active ingredients.

Trifluridine 15 mg

Trifluridine is a thymidine-based nucleoside analogue that becomes incorporated into the DNA of rapidly dividing cancer cells.

Once incorporated, it:

• Disrupts DNA synthesis
• Prevents normal DNA function
• Stops cancer cell replication
• Promotes tumor cell death

This direct DNA-targeting activity slows the growth of cancer cells and limits tumor progression.

Tipiracil 6.14 mg

Tipiracil enhances the effectiveness of trifluridine by inhibiting the enzyme thymidine phosphorylase, which normally breaks down trifluridine in the body.

By preventing this breakdown, tipiracil:

• Increases blood concentrations of trifluridine
• Extends its duration of action
• Improves overall anticancer activity
• Enhances treatment effectiveness

Together, these two medicines provide sustained exposure of cancer cells to trifluridine, maximizing therapeutic benefit.

Dosage and Administration

Trifluxen should only be taken exactly as prescribed by an oncology specialist.

Standard 28-Day Treatment Cycle

A typical treatment cycle includes:

 

Treatment Days	Dosage
Days 1–5	Take twice daily
Days 6–7	No medication
Days 8–12	Take twice daily
Days 13–28	Rest period

 

The cycle is then repeated based on the physician’s evaluation. 

When to Take Trifluxen

For optimal absorption and better gastrointestinal tolerance:

• Take each dose within one hour after the morning and evening meals
• Swallow tablets whole with water
• Do not crush, chew, or split the tablets

Individualized Dosing

Unlike fixed-dose chemotherapy, Trifluxen dosing is calculated according to the patient’s Body Surface Area (BSA).

This personalized dosing strategy helps:

• Maximize treatment effectiveness
• Reduce toxicity
• Improve patient tolerance
• Minimize unnecessary adverse reactions

Dose adjustments may be required during treatment depending on blood test results and overall patient condition.

Important Administration Instructions

Patients should always follow these recommendations:

• Swallow tablets whole.
• Never chew, crush, or break the tablets.
• Wash hands after handling the medicine.
• Handle tablets carefully because they are cytotoxic.
• Follow all disposal instructions provided by healthcare professionals.
• Never share the medication with another person.

Storage and Safe Handling

Proper storage helps preserve the medicine’s stability and safety.

Store Trifluxen by following these guidelines:

• Keep tablets in the original child-resistant container.
• Leave the silica gel desiccant inside the bottle.
• Store at room temperature.
• Protect from excessive heat, moisture, and direct sunlight.
• Keep out of reach of children and pets.
• Do not transfer tablets into another container unless instructed by your healthcare provider.

Caregivers should wear appropriate protection when handling chemotherapy medications whenever recommended.

Clinical Benefits of Trifluxen

Trifluxen represents an important advancement in oral chemotherapy for advanced gastrointestinal cancers.

Its clinical advantages include:

• Convenient oral administration at home
• Reduced need for frequent hospital visits
• Dual mechanism targeting cancer DNA and drug stabilization
• Proven activity in previously treated metastatic cancers
• Improved disease control in later treatment lines
• Potential to prolong overall survival
• Better maintenance of patient quality of life

For many patients receiving palliative cancer treatment, Trifluxen provides an effective option after standard therapies have failed.

Possible Side Effects

Like most chemotherapy medicines, Trifluxen may affect healthy rapidly dividing cells and cause adverse effects.

Common side effects include:

• Fatigue
• Weakness
• Nausea
• Vomiting
• Loss of appetite
• Diarrhea
• Anemia
• Neutropenia (low white blood cell count)
• Thrombocytopenia (low platelet count)
• Increased risk of infection

Not every patient experiences these side effects, and many can be managed with supportive care and dose adjustments.

Monitoring During Treatment

Regular monitoring is essential throughout therapy.

Patients may require:

• Complete blood count (CBC)
• Liver function tests
• Kidney function tests
• Physical examinations
• Assessment of treatment response
• Monitoring for infection or bleeding

Your oncologist may delay treatment or reduce the dose if significant side effects occur.

What to Do If You Miss a Dose

If a scheduled dose is missed:

• Do not take two doses at the same time.
• Skip the missed dose unless your doctor advises otherwise.
• Resume the regular dosing schedule.
• Contact your oncology team if you are unsure what to do.

Maintaining the prescribed treatment schedule is important for achieving the best therapeutic outcomes.

Why Trifluxen Is Important in Modern Oncology

Treatment options become increasingly limited once advanced colorectal or gastric cancers stop responding to standard chemotherapy and targeted therapies.

Trifluxen provides a clinically valuable later-line treatment by:

• Targeting tumor DNA directly
• Increasing drug exposure through enzyme inhibition
• Offering convenient oral administration
• Helping delay disease progression
• Supporting longer survival
• Reducing dependence on intravenous chemotherapy and frequent hospital visits

Its unique combination of efficacy, convenience, and manageable safety profile has made it an important option in contemporary gastrointestinal cancer management.

Final Summary

Trifluxen 15 mg + 6.14 mg is an oral chemotherapy medicine containing Trifluridine 15 mg and Tipiracil 6.14 mg, manufactured by Everest Pharmaceuticals Ltd. It is indicated for adults with previously treated metastatic colorectal cancer (mCRC) and advanced gastric or gastroesophageal junction adenocarcinoma whose disease has progressed despite standard therapies.

By combining direct inhibition of cancer cell DNA replication with enhanced drug stability, Trifluxen delivers sustained anticancer activity in later-line treatment settings. Its individualized dosing, convenient oral administration, and demonstrated clinical benefit make it an important therapeutic option for patients with advanced gastrointestinal cancers seeking continued disease control and improved quality of life under specialist supervision.